Business Context and Reporting Period
This Form 8-K filing by Gossamer Bio, Inc. (Delaware) covers the date of February 12, 2019. The report details corporate governance amendments executed in connection with the closing of the Company's initial public offering (IPO).
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on legal and structural changes rather than financial performance data.
Material Changes
On February 12, 2019, the Company filed an Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws. Key changes include:
- Capital Structure: Increased authorized common stock to 700,000,000 shares and authorized 70,000,000 shares of undesignated preferred stock.
- Preferred Stock: Eliminated all references to previously existing series of convertible preferred stock.
- Board Structure: Established a classified board of directors with three classes serving staggered three-year terms.
- Director Removal: Directors may now only be removed for cause by a two-thirds vote of outstanding capital stock.
- Stockholder Action: Eliminated the ability of stockholders to take action by written consent in lieu of a meeting.
- Legal Forum: Designated the Court of Chancery of the State of Delaware as the sole and exclusive forum for derivative actions and fiduciary duty claims.
Guidance, Outlook, and Risks
The filing contains no management commentary regarding financial guidance, future outlook, or specific risk factors beyond the structural changes noted above. No unusual items or contingencies were disclosed in this specific report.
Investor Verification Checklist
- Verify the final closing price and total capital raised in the IPO referenced in this filing.
- Confirm the exact number of shares issued and outstanding post-IPO.
- Review the full text of the Amended and Restated Certificate of Incorporation (Exhibit 3.1) for specific anti-takeover provisions.
- Check subsequent filings for the Company's first quarterly financial results following the IPO.